Invitrogen Launches Patent Licensing Program For Enabling Amplification Technology
CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced that it has signed non-exclusive agreements with New England Biolabs, Inc., QIAGEN GmbH, and Kirkegaard & Perry Laboratories, Inc. (KPL), whereby the companies have licensed Invitrogen's patented technology covering the random prime amplification of nucleic acids. Financial terms of the agreements were not disclosed.
The Invitrogen technology covered in these agreements involves methods and kits for substantially amplifying nucleic acids. It is useful in several common laboratory techniques, including random primed labeling reactions, first-strand cDNA synthesis, and whole genome amplification.
"Our random prime amplification technology is an important tool in our premier portfolio of products for genetic analysis," said Amy Butler, Invitrogen Vice President of Gene Expression Profiling. "By making this technology broadly available to other companies through licensing, we can extend the benefit to a greater number of researchers and advance this rapidly growing field of research."
For additional information on Invitrogen's random prime amplification technology and associated licensing program, please send a brief inquiry to outlicensing@invitrogen.com.
About Invitrogen
Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com.
Safe Harbor Statement
Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Potential risks and uncertainties include, but are not limited to; a) the technology may or may not benefit researchers; b) the technology may or may not advance this field of research; and the risks that the market will not accept the companies' products and services, or that the companies will be unsuccessful in their efforts to develop new products and services, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.
Copyright 2008 Business Wire All Rights Reserved.